Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125820191 | 12582019 | 1 | I | 2015 | 20160718 | 20160722 | 20160722 | EXP | US-ROCHE-1798463 | ROCHE | 39.39 | YR | F | Y | 0.00000 | 20160722 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125820191 | 12582019 | 1 | PS | KLONOPIN | CLONAZEPAM | 1 | Unknown | FOR 15 YEARS | Y | U | 17533 | ||||||||
| 125820191 | 12582019 | 2 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | 40 MG/0.8 ML (40 MILLIGRAMS), SOLUTION FOR INJECTION | Y | U | 0 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | QOW | ||||
| 125820191 | 12582019 | 3 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | 400 MG/0.8 ML (40 MILLIGRAMS), SOLUTION FOR INJECTION | Y | U | 0 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | QOW | ||||
| 125820191 | 12582019 | 4 | SS | RITALIN | METHYLPHENIDATE HYDROCHLORIDE | 1 | Unknown | 15 YEARS | Y | U | 0 | ||||||||
| 125820191 | 12582019 | 5 | SS | RITALIN | METHYLPHENIDATE HYDROCHLORIDE | 1 | Unknown | Y | U | 0 | |||||||||
| 125820191 | 12582019 | 6 | SS | LAMICTAL | LAMOTRIGINE | 1 | Unknown | Y | U | 0 | |||||||||
| 125820191 | 12582019 | 7 | C | LATUDA | LURASIDONE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125820191 | 12582019 | 8 | C | LATUDA | LURASIDONE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125820191 | 12582019 | 9 | C | LATUDA | LURASIDONE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125820191 | 12582019 | 10 | C | PRAZOSIN | PRAZOSIN | 1 | 0 | ||||||||||||
| 125820191 | 12582019 | 11 | C | ATIVAN | LORAZEPAM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125820191 | 12582019 | 1 | Anxiety |
| 125820191 | 12582019 | 2 | Psoriatic arthropathy |
| 125820191 | 12582019 | 3 | Attention deficit/hyperactivity disorder |
| 125820191 | 12582019 | 4 | Psoriatic arthropathy |
| 125820191 | 12582019 | 6 | Bipolar disorder |
| 125820191 | 12582019 | 7 | Bipolar disorder |
| 125820191 | 12582019 | 8 | Anxiety |
| 125820191 | 12582019 | 9 | Attention deficit/hyperactivity disorder |
| 125820191 | 12582019 | 10 | Post-traumatic stress disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125820191 | 12582019 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125820191 | 12582019 | Confusional state | |
| 125820191 | 12582019 | Injection site bruising | |
| 125820191 | 12582019 | Loss of consciousness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125820191 | 12582019 | 2 | 2015 | 2016 | 0 | |
| 125820191 | 12582019 | 4 | 201603 | 0 | ||
| 125820191 | 12582019 | 5 | 201603 | 0 | ||
| 125820191 | 12582019 | 6 | 201603 | 0 |